ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Machado PR, Ampuero J, Guimaraes LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM, 2010. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4: e912.
-
2.
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739–1746.
-
3.
Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350–356.
-
4.
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 1266–1272.
-
5.
Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, de Oliveira Penna G, Lima Machado PR, Talhari S, 2011. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 84: 255–260.
-
6.
Oliveira MA, Pires A da S, de Bastos RP, Lima GM, Pinto SA, Pereira LI, Pereira AJ, Abrahamsohn IA, Dorta ML, Ribeiro-Dias F, 2010. Leishmania spp. parasite isolation through inoculation of patient biopsy macerates in interferon gamma knockout mice. Rev Inst Med Trop Sao Paulo 52: 83–88.
-
7.
Cupolillo E, Grimaldi G Jr, Momen H, Beverley SM, 1995. Intergenic region typing (IRT): a rapid molecular approach to the characterization and evolution of Leishmania. Mol Biochem Parasitol 73: 145–155.
-
8.
Montalvo AM, Fraga J, Maes I, Dujardin JC, van der Auwera G, 2012. Three new sensitive and specific heat-shock protein 70 PCRs for global Leishmania species identification. Eur J Clin Microbiol Infect Dis 31: 1453–1461.
-
9.
Zauli-Nascimento RC, Miguel DC, Yokoyama-Yasunaka JK, Pereira LI, Pelli de Oliveira MA, Ribeiro-Dias F, Dorta ML, Uliana SR, 2010. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B. Trop Med Int Health 15: 68–76.
-
10.
Kumar D, Kulshrestha A, Singh R, Salotra P, 2009. In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53: 835–838.
-
11.
Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, Miranda C, Llanos-Cuentas A, Chappuis F, 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 73: 272–275.
-
12.
Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P, 2012. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis 6: e1657.
-
13.
Prajapati VK, Mehrotra S, Gautam S, Rai M, Sundar S, 2012. In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis—status of newly introduced drugs. Am J Trop Med Hyg 87: 655–657.
-
14.
Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S, 2013. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis. Am J Trop Med Hyg 89: 750–754.
-
15.
Obonaga R, Fernandez OL, Valderrama L, Rubiano LC, Castro M del M, Barrera MC, Gomez MA, Gore Saravia N, 2014. Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. Antimicrob Agents Chemother 58: 144–152.
-
16.
Hendrickx S, Eberhardt E, Mondelaers A, Rijal S, Bhattarai NR, Dujardin JC, Delputte P, Cos P, Maes L, 2015. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome. J Antimicrob Chemother 70: 3023–3026.
-
17.
Soto J, Berman J, 2006. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 100 (Suppl 1): S34–S40.
-
18.
Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodriguez-Barraquer I, Garcerant D, Prager M, Osorio L, Rojas MX, Perez M, Nicholls RS, Gore Saravia N, 2012. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 205: 684–692.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1318 | 1197 | 17 |
| Full Text Views | 349 | 15 | 0 |
| PDF Downloads | 203 | 12 | 0 |
Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis
Caroline R. Espada
Caroline R. Espada
Laboratório de Leishmanioses, Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
Search for other papers by Caroline R. Espada in
Current site
Google Scholar
PubMed
Search for other papers by Caroline R. Espada in
Current site
Google Scholar
PubMed
Fatima Ribeiro-Dias
Fatima Ribeiro-Dias
Laboratório de Imunobiologia das Leishmanioses, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Brazil.
Search for other papers by Fatima Ribeiro-Dias in
Current site
Google Scholar
PubMed
Search for other papers by Fatima Ribeiro-Dias in
Current site
Google Scholar
PubMed
Miriam L. Dorta
Miriam L. Dorta
Laboratório de Imunobiologia das Leishmanioses, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Brazil.
Search for other papers by Miriam L. Dorta in
Current site
Google Scholar
PubMed
Search for other papers by Miriam L. Dorta in
Current site
Google Scholar
PubMed
Ledice Inácia de Araújo Pereira
Ledice Inácia de Araújo Pereira
Laboratório de Imunobiologia das Leishmanioses, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Brazil.
Search for other papers by Ledice Inácia de Araújo Pereira in
Current site
Google Scholar
PubMed
Search for other papers by Ledice Inácia de Araújo Pereira in
Current site
Google Scholar
PubMed
Edgar M. de Carvalho
Edgar M. de Carvalho
Serviço de Imunologia, Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil.
Centro de Pesquisas Gonçalo Moniz, Fiocruz-Bahia, Salvador, Brazil.
Search for other papers by Edgar M. de Carvalho in
Current site
Google Scholar
PubMed
Centro de Pesquisas Gonçalo Moniz, Fiocruz-Bahia, Salvador, Brazil.
Search for other papers by Edgar M. de Carvalho in
Current site
Google Scholar
PubMed
Paulo R. Machado
Paulo R. Machado
Serviço de Imunologia, Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil.
Search for other papers by Paulo R. Machado in
Current site
Google Scholar
PubMed
Search for other papers by Paulo R. Machado in
Current site
Google Scholar
PubMed
Albert Schriefer
Albert Schriefer
Serviço de Imunologia, Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil.
Search for other papers by Albert Schriefer in
Current site
Google Scholar
PubMed
Search for other papers by Albert Schriefer in
Current site
Google Scholar
PubMed
Jenicer K. U. Yokoyama-Yasunaka
Jenicer K. U. Yokoyama-Yasunaka
Laboratório de Leishmanioses, Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
Search for other papers by Jenicer K. U. Yokoyama-Yasunaka in
Current site
Google Scholar
PubMed
Search for other papers by Jenicer K. U. Yokoyama-Yasunaka in
Current site
Google Scholar
PubMed
Adriano C. Coelho
Adriano C. Coelho
Laboratório de Leishmanioses, Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
Departamento de Biologia Animal, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil.
Search for other papers by Adriano C. Coelho in
Current site
Google Scholar
PubMed
Departamento de Biologia Animal, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil.
Search for other papers by Adriano C. Coelho in
Current site
Google Scholar
PubMed
Silvia R. B. Uliana
Silvia R. B. Uliana
Laboratório de Leishmanioses, Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
Search for other papers by Silvia R. B. Uliana in
Current site
Google Scholar
PubMed
Search for other papers by Silvia R. B. Uliana in
Current site
Google Scholar
PubMed
Leishmania (Viannia) braziliensis is the main causative species of tegumentary leishmaniasis in Brazil. In this study, we evaluated the susceptibility of 16 clinical isolates of L. (V.) braziliensis from different regions of Brazil to miltefosine in vitro. Half-maximal inhibitory concentrations of miltefosine varied from 22.9 to 144.2 μM against promastigotes and from 0.3 to 4.2 μM against intracellular amastigotes. No significant differences were found between isolates of different geographical origins. A clear correlation between the EC50 against promastigotes and amastigotes within each isolate was found. These findings contribute to the evaluation of miltefosine's potential and limitations for the treatment of tegumentary leishmaniasis in Brazil.
Author Notes
Financial support: This work was supported by grants 2011/20484-7 and 2015/09080-2, São Paulo Research Foundation (FAPESP), grant 473343/2012-6, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). CRE (2015/05130-5) and ACC (2012/14629-5) were supported by FAPESP fellowships. SRBU and EMC receive senior researcher scholarships from CNPq. FR-D is a research fellow of CNPq.
Authors' addresses: Caroline R. Espada, Jenicer K. U. Yokoyama-Yasunaka, and Silvia R. B. Uliana, Laboratório de Leishmanioses, Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil, E-mails: caroline.respada@gmail.com, jenicerk@usp.br, and srbulian@icb.usp.br. Fátima Ribeiro-Dias, Miriam L. Dorta, and Ledice Inácia de Araújo Pereira, Laboratório de Imunobiologia das Leishmanioses, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Brazil, E-mails: fatimardias@gmail.com, mledorta@gmail.com, and ledicepereira@gmail.com. Edgar M. de Carvalho, Paulo R. Machado, and Albert Schriefer, Serviço de Imunologia, Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil, E-mails: edgar@ufba.br, prlmachado@hotmail.com, and nab.schriefer@gmail.com. Adriano C. Coelho, Departamento de Biologia Animal, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil, E-mail: accoelho@unicamp.br.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Machado PR, Ampuero J, Guimaraes LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM, 2010. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4: e912.
-
2.
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739–1746.
-
3.
Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350–356.
-
4.
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 1266–1272.
-
5.
Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, de Oliveira Penna G, Lima Machado PR, Talhari S, 2011. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 84: 255–260.
-
6.
Oliveira MA, Pires A da S, de Bastos RP, Lima GM, Pinto SA, Pereira LI, Pereira AJ, Abrahamsohn IA, Dorta ML, Ribeiro-Dias F, 2010. Leishmania spp. parasite isolation through inoculation of patient biopsy macerates in interferon gamma knockout mice. Rev Inst Med Trop Sao Paulo 52: 83–88.
-
7.
Cupolillo E, Grimaldi G Jr, Momen H, Beverley SM, 1995. Intergenic region typing (IRT): a rapid molecular approach to the characterization and evolution of Leishmania. Mol Biochem Parasitol 73: 145–155.
-
8.
Montalvo AM, Fraga J, Maes I, Dujardin JC, van der Auwera G, 2012. Three new sensitive and specific heat-shock protein 70 PCRs for global Leishmania species identification. Eur J Clin Microbiol Infect Dis 31: 1453–1461.
-
9.
Zauli-Nascimento RC, Miguel DC, Yokoyama-Yasunaka JK, Pereira LI, Pelli de Oliveira MA, Ribeiro-Dias F, Dorta ML, Uliana SR, 2010. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B. Trop Med Int Health 15: 68–76.
-
10.
Kumar D, Kulshrestha A, Singh R, Salotra P, 2009. In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53: 835–838.
-
11.
Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, Miranda C, Llanos-Cuentas A, Chappuis F, 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 73: 272–275.
-
12.
Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P, 2012. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis 6: e1657.
-
13.
Prajapati VK, Mehrotra S, Gautam S, Rai M, Sundar S, 2012. In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis—status of newly introduced drugs. Am J Trop Med Hyg 87: 655–657.
-
14.
Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S, 2013. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis. Am J Trop Med Hyg 89: 750–754.
-
15.
Obonaga R, Fernandez OL, Valderrama L, Rubiano LC, Castro M del M, Barrera MC, Gomez MA, Gore Saravia N, 2014. Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. Antimicrob Agents Chemother 58: 144–152.
-
16.
Hendrickx S, Eberhardt E, Mondelaers A, Rijal S, Bhattarai NR, Dujardin JC, Delputte P, Cos P, Maes L, 2015. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome. J Antimicrob Chemother 70: 3023–3026.
-
17.
Soto J, Berman J, 2006. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 100 (Suppl 1): S34–S40.
-
18.
Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodriguez-Barraquer I, Garcerant D, Prager M, Osorio L, Rojas MX, Perez M, Nicholls RS, Gore Saravia N, 2012. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 205: 684–692.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1318 | 1197 | 17 |
| Full Text Views | 349 | 15 | 0 |
| PDF Downloads | 203 | 12 | 0 |